西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2015年
5期
1-3
,共3页
郭晓燕%尹广超%陆城华%耿佩华%鹿振辉%张惠勇
郭曉燕%尹廣超%陸城華%耿珮華%鹿振輝%張惠勇
곽효연%윤엄초%륙성화%경패화%록진휘%장혜용
慢性阻塞性肺疾病%血管内皮生长因子%血管性血友病因子%内皮素-1%川芎平喘合剂
慢性阻塞性肺疾病%血管內皮生長因子%血管性血友病因子%內皮素-1%川芎平喘閤劑
만성조새성폐질병%혈관내피생장인자%혈관성혈우병인자%내피소-1%천궁평천합제
COPD%vascular endothelial growth factor%von willebrand factor%endothelin-1%ChuanXiong PingChuan mixture
目的:探讨川芎平喘合剂对COPD患者血管内皮功能的影响。方法:将COPD患者68例按随机数字表法随机分为对照组和治疗组各34例。对照组给予常规基础治疗,治疗组在常规治疗的基础上给予川芎平喘合剂。治疗3个月后观察2组患者血管内皮生长因子(VEGF)、ET-1、vWF及中医证候积分等指标变化情况。结果:1)临床疗效比较:对照组、治疗组总有效率分别为86.7%和93.5%,2组比较差异具有统计学意义(P<0.05)。2)2组治疗后ET-1、vWF较治疗前明显下降,VEGF水平较治疗前明显升高,其差异具有统计学意义(P<0.05);治疗后治疗组ET-1、vWF较对照组明显下降,VEGF较对照组明显升高,其差异具有统计学意义(P<0.05)。3)中医症状积分:治疗后2组患者中医症状积分均较治疗前明显降低(P<0.05);治疗组治疗后症状积分较对照组明显降低,其差异具有统计学意义(P<0.05)。结论:川芎平喘合剂可缓解COPD患者症状,调节、改善患者血管内皮功能,其机制可能与调节vWF、VEGF水平,抑制ET-1分泌有关。
目的:探討川芎平喘閤劑對COPD患者血管內皮功能的影響。方法:將COPD患者68例按隨機數字錶法隨機分為對照組和治療組各34例。對照組給予常規基礎治療,治療組在常規治療的基礎上給予川芎平喘閤劑。治療3箇月後觀察2組患者血管內皮生長因子(VEGF)、ET-1、vWF及中醫證候積分等指標變化情況。結果:1)臨床療效比較:對照組、治療組總有效率分彆為86.7%和93.5%,2組比較差異具有統計學意義(P<0.05)。2)2組治療後ET-1、vWF較治療前明顯下降,VEGF水平較治療前明顯升高,其差異具有統計學意義(P<0.05);治療後治療組ET-1、vWF較對照組明顯下降,VEGF較對照組明顯升高,其差異具有統計學意義(P<0.05)。3)中醫癥狀積分:治療後2組患者中醫癥狀積分均較治療前明顯降低(P<0.05);治療組治療後癥狀積分較對照組明顯降低,其差異具有統計學意義(P<0.05)。結論:川芎平喘閤劑可緩解COPD患者癥狀,調節、改善患者血管內皮功能,其機製可能與調節vWF、VEGF水平,抑製ET-1分泌有關。
목적:탐토천궁평천합제대COPD환자혈관내피공능적영향。방법:장COPD환자68례안수궤수자표법수궤분위대조조화치료조각34례。대조조급여상규기출치료,치료조재상규치료적기출상급여천궁평천합제。치료3개월후관찰2조환자혈관내피생장인자(VEGF)、ET-1、vWF급중의증후적분등지표변화정황。결과:1)림상료효비교:대조조、치료조총유효솔분별위86.7%화93.5%,2조비교차이구유통계학의의(P<0.05)。2)2조치료후ET-1、vWF교치료전명현하강,VEGF수평교치료전명현승고,기차이구유통계학의의(P<0.05);치료후치료조ET-1、vWF교대조조명현하강,VEGF교대조조명현승고,기차이구유통계학의의(P<0.05)。3)중의증상적분:치료후2조환자중의증상적분균교치료전명현강저(P<0.05);치료조치료후증상적분교대조조명현강저,기차이구유통계학의의(P<0.05)。결론:천궁평천합제가완해COPD환자증상,조절、개선환자혈관내피공능,기궤제가능여조절vWF、VEGF수평,억제ET-1분비유관。
Objective:To find out the effects of ChuanXiong PingChuan mixture on vascular endothelial func-tion of COPD patients. Methods:Sixty-eight patients were allocated to the control group and the treatment group ac-cording to random number table method, 34 cases in each group. The control group received routine treatment, and the treatment group took ChuanXiong PingChuan mixture on the basis of routine treatment. To observe vascular en-dothelial growth factor (VEGF), endothelin-1 (ET-1), von willebrand factor (vWF) and syndrome scales of the pa-tients in both groups before and after treating for three months. Results:1) the comparison of clinical effects:total ef-fective rates of the control group and the treatment group were 86.7%and 93.5%respectively, the difference had sta-tistical meaning between both groups(P<0.05). 2) The levels of ET-1 and vWF lowered after treating in both groups than these indexes before treating, the level of VEGF increased significantly compared with before treating, the dif-ference showed statistical meaning (P<0.05);after treating, the levels of ET-1 and vWF of the treatment group de-creased compared with the control group, the levels of VEGF in the treatment group improved compared with that of the control group, the difference demonstrated statistical meaning (P<0.05). 3) TCM symptom integral:symptom in-tegrals of both groups after treating were lower than these before treating obviously (P<0.05);symptom integral of the treatment group after treating was reduced evidently compared with the control group notably, the difference pre-sented statistical meaning (P<0.05). Conclusion: ChuanXiong PingChuan mixture could alleviate COPD patients' symptoms, regulate and improve vascular endothelial function of the patients, and its mechanism might be related to regulating the levels of vWF and VEGF, inhibiting the secretion of ET-1.